Skip to content
Lower risk Drug recall · FDA · Published February 12, 2024

MCKESSON CABTREO Gel Recall: Storage Temperature Risk

MCKESSON recalls CABTREO topical gel due to improper storage causing potential product degradation. This prescription-only acne treatment may be unsafe if not kept refrigerated.

🇺🇸 FDA recall #D-0347-2024DrugMCKESSON ›
Take action

Contact the company

Recalling firmMCKESSON CORPORATION6555 NORTH STATE HIGHWA · IRVING, TX 75039
✎ GovInfoNow plain-language explainer

MCKESSON is recalling CABTREO topical gel because it was stored at room temperature instead of refrigerated. This could cause the medication to degrade, making it less effective or potentially unsafe for acne treatment. Read more at govinfonow.com/recall/32820-mckesson-cabtreo-gel-recall-storage-temperature-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/32820-mckesson-cabtreo-gel-recall-storage-temperature-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0347-2024

Cite this page

“MCKESSON CABTREO Gel Recall: Storage Temperature Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32820-mckesson-cabtreo-gel-recall-storage-temperature-risk. Based on FDA recall #D-0347-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0347-2024%22&limit=1).

The FDA announced on Feb. 12, 2024, that McKesson Corporation voluntarily recalled CABTREO topical gel due to CGMP deviations involving improper storage temperatures. The agency classified the recall as Class II.

How to tell if you have it

  • Brand: MCKESSON
  • Product: CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%
  • NDC: 0187-0006-25
  • Lot code: 7001796
  • Expiration date: 05/31/2025
  • Net weight: 50g
  • Units affected: 42
  • Distribution: Nationwide in the US

The hazard

The product was stored outside labeled storage temperature requirements, exposing it to a controlled room temperature environment instead of remaining refrigerated. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show McKesson Corporation has one other recall on record since Aug. 14, 2018, involving Megestrol Acetate Oral Suspension due to superpotent drug risk. Other recent recalls of similar products include McKesson Gemcitabine Injection Recall (June 10, 2026) and McKesson Recalls UDENYCA Injection Due to Temperature Abuse Risk (Jan. 16, 2026).

How to tell if you have this one

Check for CABTREO topical gel with lot number 7001796. This product is prescription-only and sold in 50g containers.

  • Brand
    MCKESSON
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the lot number on your CABTREO gel container to see if it matches 7001796.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 8 months after the firm started it.

1. Firm started the recall: Feb 12, 202412. FDA classified it Class II: Feb 22, 202423. Published in FDA’s Enforcement Report: Feb 28, 202434. FDA terminated the recall: Oct 1, 202442024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

How long is this product expected to last?

The product expires May 31, 2025, but the recall is for improper storage, not expiration.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0347-2024 (February 12, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0347-2024 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA